MRI contrast dye may skew brain scans, study finds
NCT ID NCT04906941
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at how gadolinium, a dye used in MRI scans, changes the QSM signal in the brain's white matter. 73 patients with inflammatory central nervous system conditions had MRI scans before and after receiving gadolinium. The goal was to measure any differences in the signal, which could help doctors better understand and interpret future scans.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- gadolinium (contrast agent)
- What this could lead to
- If successful, this could help doctors interpret MRI scans more accurately in patients with white matter disease.
- What could go wrong
- This is a small, completed observational study, not a treatment trial. Results may not apply to all patients or MRI machines.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
73 people
The number who actually took part.
- Started
-
Jan 2022
- Finished
-
Jul 2023
- Lead sponsor
-
A research network
The lead sponsor is a research network or cooperative group.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients meeting the inclusion and non-inclusion criteria will be offered to participate in the study. If they agree, they will perform an MRI without injection to obtain the QSM then perform the MRI with injection that was prescribed to them as part of the care, then they will perform a second time the MRI without injection to obtain the QSM. They will also answer a short questionnaire documenting their previous exposure to gadolinium.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * patients over 18 years old * with an inflammatory CNS pathology * to benefit as part of care from an MRI with injection of gadolinium * consent to participate in the study * beneficiary of a social protection scheme Exclusion Criteria: * pregnant or breastfeeding woman * patient benefiting from a legal protection measure * Patient having performed more than 3 MRI exams with gadolinium injection during his life Secondary exclusion criteria : * motion artifact not allowing image interpretation * patient who has not completed one of the following sequences: T1 anatomical, FLAIR, or QSM pre-gadolinium injection. Secondarily excluded patients will be replaced up to a maximum of 25 patients.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Inflammatory CNS pathology are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hhopital fondation adolphe de rothschild
Paris, Paris, 75019, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.